James C Metcalfe

This inventor holds 20 USPTO granted patents, primarily in Cardiovascular Therapies. Top assignees: Neorx Corporation, Noerx Corporation, Poniard Pharmaceuticals, Inc.. Active years: 1995-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James C Metcalfe. Retrieved from https://idiyas.com/inventor/james-c-metcalfe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20

% Patents Active = 85.0

Average Co-Inventor Count = 3.4

ph-index = 17

Forward Citations = 1,729(Granted Patents)

Company Filing History:

Poniard Pharmaceuticals, Inc.

patents

Years Active: 1995-2009

Loading Chart...

Areas of Expertise:

Cardiovascular Pathologies

Vascular Smooth Muscle Cells

Tamoxifen Analogues

TGF-Beta Levels

Compounds

Therapies

Inhibitors

Prevention

Treatment

Pathologies

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7511070 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2009-03-31),

2. 7084171 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2006-08-01),

3. 6734208 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2004-05-11),

4. 6410587 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2002-06-25),

5. 6262079 - Prevention and treatment of cardiovascular pathologies (2001-07-17),

6. 6251920 - Prevention and treatment of cardiovascular pathologies (2001-06-26),

7. 6197789 - Prevention and treatment of cardiovascular pathologies with tamoxifen analogues (2001-03-06),

8. 6166090 - Prevention and treatment of pathologies associated with abnormally (2000-12-26),

9. 6117911 - Compounds and therapies for the prevention of vascular and non-vascular (2000-09-12),

10. 6074659 - Therapeutic inhibitor of vascular smooth muscle cells (2000-06-13),

11. 5945456 - Prevention and treatment of pathologies associated with abnormally (1999-08-31),

12. 5847007 - Prevention and treatment of pathologies associated with abnormally (1998-12-08),

13. 5811447 - Therapeutic inhibitor of vascular smooth muscle cells (1998-09-22),

14. 5773479 - Prevention and treatment of pathologies associated with abnormally (1998-06-30),

15. 5770609 - Prevention and treatment of cardiovascular pathologies (1998-06-23),

Title: James C Metcalfe: Innovator in Therapeutic Compounds

Introduction

James C Metcalfe, based in Cambridge, GB, is an accomplished inventor known for his significant contributions to the field of medical therapeutics. With a remarkable portfolio comprising 20 patents, Metcalfe has dedicated his career to developing innovative treatments that address critical health issues.

Latest Patents

Among his latest achievements, Metcalfe has focused on compounds and therapies aimed at preventing vascular and non-vascular pathologies. His invention outlines a method for treating mammals that exhibit indications associated with a TGF-beta deficiency. This method involves administering one or more agents that effectively elevate TGF-beta levels. Additionally, his work includes the development of novel compounds that enhance TGF-beta levels, pharmaceutical compositions utilizing these compounds, and methodologies for detecting diseases linked to endothelial cell activation.

Career Highlights

Throughout his career, Metcalfe has made impressive strides in the pharmaceutical industry, contributing valuable research and innovations. He has worked with notable companies, including Neorx Corporation, where he collaborated on various projects aimed at advancing therapeutic solutions and improving patient outcomes.

Collaborations

Metcalfe's journey also includes collaboration with esteemed colleagues such as David John Grainger and Peter L Weissberg. These partnerships have fostered an environment of innovation, allowing for the exchange of ideas and expertise in the field of pharmacology.

Conclusion

James C Metcalfe's dedication to innovation in medical therapies has established him as a prominent figure in his field. With numerous patents securing his contributions, his work continues to shape the future of therapeutic treatments, particularly in addressing deficiencies that impact mammalian health. His collaborative spirit and commitment to research reflect the vital role inventors play in advancing healthcare solutions.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]